BiotechTube

DS-8201a + Ritonavir + Itraconazole

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm Metastasis

Conditions

Neoplasm Metastasis

Trial Timeline

Jan 12, 2018 → Sep 11, 2023

NCT ID
NCT03383692

About DS-8201a + Ritonavir + Itraconazole

DS-8201a + Ritonavir + Itraconazole is a phase 1 stage product being developed by Daiichi Sankyo for Neoplasm Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03383692. Target conditions include Neoplasm Metastasis.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasm Metastasis were approved

Approved (20) Terminated (3) Active (0)
✅LenvatinibEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Chlorhydrate de RopivacaineAstraZenecaApproved
✅Sitagliptin + placeboMerckApproved
✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03383692Phase 1Completed

Competing Products

20 competing products in Neoplasm Metastasis

See all competitors
ProductCompanyStageHype Score
ADC-1013Alligator Bioscience ABPhase 1
19
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
AB0024Gilead SciencesPhase 1
29
TTI-237PfizerPhase 1
21
852APfizerPhase 1
29
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
21
LY2780301Eli LillyPhase 1
29
PemetrexedEli LillyPhase 2
35
pemetrexed + cisplatinEli LillyPhase 1/2
32
IMC-3C5Eli LillyPhase 1
29
LY3295668Eli LillyPhase 1/2
32
Abemaciclib + ClarithromycinEli LillyPhase 1
29
Abemaciclib + FulvestrantEli LillyPhase 2
27
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
32
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + LeucovorinEli LillyPhase 1
29
LY2784544Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
enzastaurinEli LillyPhase 2
35